Registry for Multiple Endocrine Neoplasia Syndromes: MEN1/MEN2

Previously followed MEN1 and MEN2 patients at M.D. Anderson Cancer Center will be mailed an
introductory letter and a "consent to be contacted" form to determine whether they are
interested in participating in the study. New MEN1 and MEN2 patients seen in clinic at M.D.
Anderson Cancer Center will be asked if they wish to learn more about this study. Interested
patients will also be asked to distribute the introductory letter and consent to be contacted
form to their blood relatives. Printed materials regarding this study will only be mailed to
non-MDACC individuals with the expressed written or verbal permission from a consenting MDACC
patient. All interested individuals will return the signed "consent to be contacted" form to
the PI. Consented individuals will be interviewed by phone and/or mail to obtain updated
family and medical history specific to their diagnosis of either MEN1 or MEN2. To verify
accuracy of medical data collected, all non-MDACC participants will be asked if they consent
to have their off-site medical records released to us for review. There will be no treatment
or collection of blood or tissue in this study.

Although this study presents minimal risk to participants, participant consent will be
obtained due to the need to obtain permission to make contact with patients and their
families.

Approximately 1500 patients and their relatives will be included in this study. This will be
done on an inpatient and outpatient basis.

Inclusion Criteria:

1. Registered MDACC patients diagnosed with MEN1 or MEN2.

2. Close relatives of registered MDACC MEN patients.

Exclusion Criteria:

1. Individuals who are either non-MDACC registered patients or do not have a close relative
who is an MEN patient registered at MDACC.